SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes inspection at Glenmark Pharmaceuticals’ Aurangabad facility with one observation

02 Jul 2022 Evaluate

The United States Food and Drug Administration (USFDA) has issued Form 483 with one observation after an inspection at Glenmark Pharmaceuticals’ formulation manufacturing facility based out of Aurangabad, India between June 27, 2022 and July 1, 2022. 

The company is committed to undertake all necessary steps required to address their observation at the earliest. The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

2247.90 -1.65 (-0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×